Palisades Investment Partners LLC Has $3.68 Million Position in Delcath Systems, Inc. $DCTH

Palisades Investment Partners LLC raised its position in shares of Delcath Systems, Inc. (NASDAQ:DCTH) by 58.0% in the second quarter, Holdings Channel reports. The fund owned 270,310 shares of the company’s stock after buying an additional 99,226 shares during the quarter. Delcath Systems comprises approximately 1.6% of Palisades Investment Partners LLC’s investment portfolio, making the stock its 23rd biggest holding. Palisades Investment Partners LLC’s holdings in Delcath Systems were worth $3,676,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of the company. Inlight Wealth Management LLC acquired a new position in shares of Delcath Systems in the 1st quarter valued at $85,000. NBC Securities Inc. raised its position in shares of Delcath Systems by 99,900.0% in the first quarter. NBC Securities Inc. now owns 10,000 shares of the company’s stock valued at $127,000 after buying an additional 9,990 shares in the last quarter. Quantbot Technologies LP lifted its position in shares of Delcath Systems by 212.8% during the 1st quarter. Quantbot Technologies LP now owns 17,108 shares of the company’s stock worth $218,000 after buying an additional 11,638 shares during the last quarter. Cannon Global Investment Management LLC bought a new position in Delcath Systems in the first quarter valued at about $239,000. Finally, Jefferies Financial Group Inc. bought a new position in shares of Delcath Systems during the fourth quarter worth about $251,000. Institutional investors own 61.12% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms recently commented on DCTH. HC Wainwright increased their price target on Delcath Systems from $29.00 to $31.00 and gave the company a “buy” rating in a research report on Thursday, August 7th. Wall Street Zen cut Delcath Systems from a “buy” rating to a “hold” rating in a report on Sunday, August 10th. Finally, Stephens reaffirmed an “overweight” rating and set a $25.00 price target on shares of Delcath Systems in a research report on Monday, June 23rd. Four analysts have rated the stock with a Buy rating, Based on data from MarketBeat, Delcath Systems currently has a consensus rating of “Buy” and an average target price of $24.50.

Delcath Systems Stock Down 1.1%

NASDAQ:DCTH opened at $10.74 on Friday. The stock’s 50-day moving average price is $10.97 and its 200-day moving average price is $12.63. Delcath Systems, Inc. has a 52 week low of $8.08 and a 52 week high of $18.23. The stock has a market capitalization of $375.70 million, a PE ratio of 214.80 and a beta of 0.85.

Delcath Systems (NASDAQ:DCTH) last posted its quarterly earnings results on Wednesday, August 6th. The company reported $0.07 EPS for the quarter, topping the consensus estimate of $0.02 by $0.05. Delcath Systems had a net margin of 3.18% and a return on equity of 6.91%. The business had revenue of $24.16 million during the quarter, compared to the consensus estimate of $22.84 million. Sell-side analysts expect that Delcath Systems, Inc. will post -0.79 earnings per share for the current fiscal year.

About Delcath Systems

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.